For established PD risk factors, it is recognized that rare highly penetrant Mendelian variants (eg, homozygous PARK2 mutations) typically lead to a reduced AAO when compared to less penetrant disease mutations (eg, G2019S at LRRK2). The gene discussed is PRKN; the disease is Parkinson disease.